CoChat
Sign Up
Cited by 197

The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.

Senescence as a therapeutic target in cancer and age-related diseases

McHugh, Domhnall, Durán, Imanol, Gil, Jesús·2025·Nature Reviews Drug Discovery
DOI 10.1038/s41573-024-01074-4
Open this paper in CoChat — free account

Abstract

Cellular senescence is a stress response that restrains the growth of aged, damaged or abnormal cells. Thus, senescence has a crucial role in development, tissue maintenance and cancer prevention. However, lingering senescent cells fuel chronic inflammation through the acquisition of a senescence-associated secretory phenotype (SASP), which contributes to cancer and age-related tissue dysfunction. Recent progress in understanding senescence has spurred interest in the development of approaches to target senescent cells, known as senotherapies. In this Review, we evaluate the status of various types of senotherapies, including senolytics that eliminate senescent cells, senomorphics that suppress the SASP, interventions that mitigate senescence and strategies that harness the immune system to clear senescent cells. We also summarize how these approaches can be combined with cancer therapies, and we discuss the challenges and opportunities in moving senotherapies into clinical practice. Such therapies have the potential to address root causes of age-related diseases and thus open new avenues for preventive therapies and treating multimorbidities.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41573-024-01074-4

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 95

  1. Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37, 614–636 (1965). · DOI · Paper page
  2. Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961). This article is a pioneering study that defines the concept of cellular senescence. · DOI · Paper page
  3. Chang, B. D. et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18, 4808–4818 (1999). · DOI
  4. Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335–346 (2002). Together with Chang et al. (1999), this work describes the concept of TIS in human cells and mouse models for the first time. · DOI · Paper page
  5. Lee, S. et al. Virus-induced senescence is a driver and therapeutic target in COVID-19. Nature 599, 283–289 (2021). · DOI · Paper page
  6. Storer, M. et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 155, 1119–1130 (2013). · DOI · Paper page
  7. Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27–37 (1996). · DOI · Paper page
  8. Sharpless, N. E. & Sherr, C. J. Forging a signature of in vivo senescence. Nat. Rev. Cancer 15, 397–408 (2015). · DOI · Paper page
  9. Kaplon, J. et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498, 109–112 (2013). · DOI · Paper page
  10. Kondoh, H. et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 65, 177–185 (2005). · DOI · Paper page
  11. Chandra, T. & Narita, M. High-order chromatin structure and the epigenome in SAHFs. Nucleus 4, 23–28 (2013). · DOI
  12. Coppe, J. P., Desprez, P. Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118 (2010). · DOI · Paper page
  13. Ritschka, B. et al. The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration. Genes. Dev. 31, 172–183 (2017). · DOI · Paper page
  14. Grosse, L. et al. Defined p16High senescent cell types are indispensable for mouse healthspan. Cell Metab. 378, 87–99.e6 (2020). Together with Reyes et al. (2022), this work is the first study to describe a detrimental effect associated with eliminating specific populations of SnCs. · DOI · Paper page
  15. Helman, A. et al. p16Ink4a-induced senescence of pancreatic β cells enhances insulin secretion. Nat. Med. 22, 412–420 (2016). · DOI · Paper page
  16. Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 22, 340–355 (2022). This important Review summarizes the use of senotherapies for cancer. · DOI · Paper page
  17. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006). · DOI · Paper page
  18. Di Mitri, D. et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature 515, 134–137 (2014). Together with Eggert et al. (2016), this work is the first study to describe the SASP-driven recruitment of immunosuppressive MDSCs. · DOI · Paper page
  19. D’Ambrosio, M. & Gil, J. Reshaping of the tumor microenvironment by cellular senescence: an opportunity for senotherapies. Dev. Cell 58, 1007–1021 (2023). · DOI
  20. Yasuda, T. et al. Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination. Cell Rep. 34, 108779 (2021). · DOI · Paper page
  21. Prieto, L. I. et al. Senescent alveolar macrophages promote early-stage lung tumorigenesis. Cancer Cell 41, 1261–1275.e6 (2023). · DOI · Paper page
  22. Maggiorani, D. et al. Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment. Nat. Commun. 15, 2435 (2024). · DOI
  23. Wang, T. W. et al. Blocking PD-L1–PD-1 improves senescence surveillance and ageing phenotypes. Nature 611, 358–364 (2022). · DOI · Paper page
  24. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995). · DOI · Paper page
  25. Burd, C. E. et al. Monitoring tumorigenesis and senescence in vivo with a p16INK4a-luciferase model. Cell 152, 340–351 (2013). · DOI · Paper page
  26. Jeyapalan, J. C., Ferreira, M., Sedivy, J. M. & Herbig, U. Accumulation of senescent cells in mitotic tissue of aging primates. Mech. Ageing Dev. 128, 36–44 (2007). · DOI · Paper page
  27. Tanaka, T. et al. Plasma proteomic signature of age in healthy humans. Aging Cell 17, e12799 (2018). · DOI · Paper page
  28. Narasimhan, A., Flores, R. R., Robbins, P. D. & Niedernhofer, L. J. Role of cellular senescence in type II diabetes. Endocrinology 162, bqab136 (2021). · DOI · Paper page
  29. Minamino, T. et al. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105, 1541–1544 (2002). · DOI · Paper page
  30. Papatheodoridi, A. M., Chrysavgis, L., Koutsilieris, M. & Chatzigeorgiou, A. The role of senescence in the development of nonalcoholic fatty liver disease and progression to nonalcoholic steatohepatitis. Hepatology 71, 363–374 (2020). · DOI
  31. Dungan, C. M. et al. Deletion of SA β-Gal+ cells using senolytics improves muscle regeneration in old mice. Aging Cell 21, e13528 (2022). · DOI
  32. Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78–83 (2016). · DOI · Paper page
  33. Wang, B. et al. An inducible p21-Cre mouse model to monitor and manipulate p21-highly-expressing senescent cells in vivo. Nat. Aging 1, 962–973 (2021). · DOI · Paper page
  34. Lee, S. et al. A guide to senolytic intervention in neurodegenerative disease. Mech. Ageing Dev. 200, 111585 (2021). · DOI
  35. Childs, B. G. et al. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science 354, 472–477 (2016). · DOI · Paper page
  36. Bigenwald, C. et al. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat. Med. 27, 851–861 (2021). · DOI · Paper page
  37. Pospelova, T. V. et al. Suppression of replicative senescence by rapamycin in rodent embryonic cells. Cell Cycle 11, 2402–2407 (2012). · DOI
  38. Khosla, S. Senescent cells, senolytics and tissue repair: the devil may be in the dosing. Nat. Aging 3, 139–141 (2023). · DOI
  39. Wang, E. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res. 55, 2284–2292 (1995).
  40. Zhu, Y. et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell 15, 428–435 (2016). Together with Chang et al. (2016) and Yosef et al. (2016), this study is the first description of the use of BCL-2 inhibitors as senolytics. · DOI · Paper page
  41. Jia, Y. et al. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 108, 2626–2638 (2023). · DOI
  42. He, Y. et al. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat. Commun. 11, 1996 (2020).
  43. Thompson, P. J. et al. Targeted elimination of senescent β cells prevents type 1 diabetes. Cell Metab. 29, 1045–1060.e10 (2019). · DOI · Paper page
  44. Troiani, M. et al. Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer. Nat. Commun. 13, 2177 (2022). · DOI
  45. Wang, L. et al. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis. Nat. Cancer 3, 1284–1299 (2022). · DOI
  46. Agostini, A. et al. Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles. Angew. Chem. Int. Ed. Engl. 51, 10556–10560 (2012). · DOI
  47. Guerrero, A. et al. Galactose-modified duocarmycin prodrugs as senolytics. Aging Cell 19, e13133 (2020). · DOI · Paper page
  48. Efeyan, A. et al. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res. 67, 7350–7357 (2007). · DOI · Paper page
  49. Dolgin, E. Send in the senolytics. Nat. Biotechnol. 38, 1371–1377 (2020). · DOI
  50. Li, M., Brooks, C. L., Kon, N. & Gu, W. A dynamic role of HAUSP in the p53–Mdm2 pathway. Mol. Cell 13, 879–886 (2004). · DOI · Paper page
  51. He, Y. et al. Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity. Aging Cell 19, e13117 (2020).
  52. Le, H. H. et al. Molecular modelling of the FOXO4–TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine 73, 103646 (2021). · DOI
  53. Fuhrmann-Stroissnigg, H. et al. Identification of HSP90 inhibitors as a novel class of senolytics. Nat. Commun. 8, 422 (2017). · DOI · Paper page
  54. McHugh, D. et al. COPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cells. Nat. Cell Biol. 25, 1804–1820 (2023). · DOI
  55. Jackson, L. P. Structure and mechanism of COPI vesicle biogenesis. Curr. Opin. Cell Biol. 29, 67–73 (2014). · DOI
  56. Johmura, Y. et al. Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders. Science 371, 265–270 (2021). · DOI · Paper page
  57. Therien, A. G. & Blostein, R. Mechanisms of sodium pump regulation. Am. J. Physiol. Cell Physiol. 279, C541–C566 (2000). · DOI · Paper page
  58. Russo, G. L. et al. Mechanisms of aging and potential role of selected polyphenols in extending healthspan. Biochem. Pharmacol. 173, 113719 (2020). · DOI
  59. Roos, C. M. et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15, 973–977 (2016). · DOI · Paper page
  60. Yousefzadeh, M. J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36, 18–28 (2018). · DOI · Paper page
  61. Ovadya, Y. et al. Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat. Commun. 9, 5435 (2018). · DOI · Paper page
  62. Prieto, L. I., Sturmlechner, I., Goronzy, J. J. & Baker, D. J. Senescent cells as thermostats of antitumor immunity. Sci. Transl. Med. 15, eadg7291 (2023). · DOI
  63. Hasegawa, T. et al. Cytotoxic CD4+ T cells eliminate senescent cells by targeting cytomegalovirus antigen. Cell 186, 1417–1431.e20 (2023). · DOI
  64. Chen, H. A. et al. Senescence rewires microenvironment sensing to facilitate antitumor immunity. Cancer Discov. 13, 432–453 (2023). · DOI
  65. Shahbandi, A. et al. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat. Cancer 3, 1513–1533 (2022). · DOI
  66. Poblocka, M. et al. Targeted clearance of senescent cells using an antibody–drug conjugate against a specific membrane marker. Sci. Rep. 11, 20358 (2021). · DOI · Paper page
  67. Suda, M. et al. Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells. Sci. Rep. 12, 6522 (2022).
  68. Yang, D. et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci. Transl. Med. 15, eadd1951 (2023). · DOI · Paper page
  69. Yoshida, S. et al. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nat. Commun. 11, 2482 (2020).
  70. Marin, I. et al. Cellular senescence is immunogenic and promotes antitumor immunity. Cancer Discov. 13, 410–431 (2023). · DOI
  71. Vizioli, M. G. et al. Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence. Genes. Dev. 34, 428–445 (2020). · DOI · Paper page
  72. Rodier, F. et al. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J. Cell Sci. 124, 68–81 (2011). · DOI · Paper page
  73. Widjaja, A. A. et al. Inhibition of IL-11 signalling extends mammalian healthspan and lifespan. Nature 632, 157–165 (2024). · DOI · Paper page
  74. Ogata, A., Kato, Y., Higa, S. & Yoshizaki, K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod. Rheumatol. 29, 258–267 (2019). · DOI
  75. Del Rey, M. J. et al. Senescent synovial fibroblasts accumulate prematurely in rheumatoid arthritis tissues and display an enhanced inflammatory phenotype. Immun. Ageing 16, 29 (2019). · DOI
  76. Ruscetti, M. et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362, 1416–1422 (2018). · DOI · Paper page
  77. Ruscetti, M. et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell 181, 424–441.e21 (2020). · DOI · Paper page
  78. Chibaya, L. et al. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Nat. Cancer 4, 872–892 (2023). · DOI
  79. Blagosklonny, M. V. Rapamycin, proliferation and geroconversion to senescence. Cell Cycle 17, 2655–2665 (2018). · DOI
  80. Aguado, J. et al. Inhibition of DNA damage response at telomeres improves the detrimental phenotypes of Hutchinson–Gilford progeria syndrome. Nat. Commun. 10, 4990 (2019). · DOI · Paper page
  81. Bousset, L. & Gil, J. Targeting senescence as an anticancer therapy. Mol. Oncol. 16, 3855–3880 (2022). · DOI
  82. Ou, H. L. et al. Cellular senescence in cancer: from mechanisms to detection. Mol. Oncol. 15, 2634–2671 (2021). · DOI
  83. Chambers, C. R., Ritchie, S., Pereira, B. A. & Timpson, P. Overcoming the senescence-associated secretory phenotype (SASP): a complex mechanism of resistance in the treatment of cancer. Mol. Oncol. 15, 3242–3255 (2021). · DOI
  84. Fleury, H. et al. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat. Commun. 10, 2556 (2019). · DOI · Paper page
  85. Kolodkin-Gal, D. et al. Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesions. Gut 71, 345–355 (2021). · DOI
  86. Alvarez-Fernandez, M. & Malumbres, M. Mechanisms of sensitivity and resistance to CDK4/6 inhibition. Cancer Cell 37, 514–529 (2020). · DOI
  87. Baell, J. B. et al. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature 560, 253–257 (2018). · DOI
  88. Heckenbach, I. et al. Nuclear morphology is a deep learning biomarker of cellular senescence. Nat. Aging 2, 742–755 (2022). · DOI · Paper page
  89. Duran, I. et al. Detection of senescence using machine learning algorithms based on nuclear features. Nat. Commun. 15, 1041 (2024). Together with Heckenbach et al. (2022) and Kusumoto et al. (2021), this work reports the use of a machine learning analysis of morphological parameters to detect SnCs. · DOI · Paper page
  90. Cui, W., Liu, L., Kodibagkar, V. D. & Mason, R. P. S-Gal, a novel 1H MRI reporter for β-galactosidase. Magn. Reson. Med. 64, 65–71 (2010). · DOI
  91. Wiley, C. D. et al. Oxylipin biosynthesis reinforces cellular senescence and allows detection of senolysis. Cell Metab. 33, 1124–1136.e5 (2021). This article provides a description of a biomarker of senolysis that can be detected in the blood. · DOI · Paper page
  92. Ohtani, N., Yamakoshi, K., Takahashi, A. & Hara, E. Real-time in vivo imaging of p16 gene expression: a new approach to study senescence stress signaling in living animals. Cell Div. 5, 1 (2010). · DOI
  93. Ohtani, N. et al. Visualizing the dynamics of p21Waf1/Cip1 cyclin-dependent kinase inhibitor expression in living animals. Proc. Natl Acad. Sci. USA 104, 15034–15039 (2007). · DOI · Paper page
  94. Liu, J. Y. et al. Cells exhibiting strong p16INK4a promoter activation in vivo display features of senescence. Proc. Natl Acad. Sci. USA 116, 2603–2611 (2019). · DOI · Paper page
  95. Hori, N. et al. Shaving black fur uncovers hidden issues in p16-3MR mice. Preprint at bioRxiv https://doi.org/10.1101/2024.06.24.600181 (2024). · DOI

Cited by

Sorted by citations

See all 197

Metadata

Authors
McHugh, D., Durán, I., & Gil, J.
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2024-11-15
Volume
24
Issue
1
Pages
57-71
ISSN
  • 1474-1776
  • 1474-1784
DOI
10.1038/s41573-024-01074-4
Cited by
197
References
103
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review